A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial
VHIO24001
Phase 1 other active
Quick answer
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial for Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+) is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)
- Phase
- Phase 1
- Modality
- other
- Status
- active